Infusion-related reactions to rituximab: frequency, mechanisms and predictors

References

• Feugier P. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin’s lymphomas. Future Oncol. 2015;11(9):1327–1342.
   PubMed Web of Science ®Google Scholar
• James DF, Kipps TJ. Rituximab in chronic lymphocytic leukemia. Adv Ther. 2011;28(7):534–554.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002;29(1S2):2–9.
   Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47(2):115–123.
   PubMed Web of Science ®Google Scholar
• Cartron G, Watier H, Golay J, et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104(9):2635–2642.
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754–758.
   PubMed Web of Science ®Google Scholar
• Doessegger L, Banholzer ML. Clinical development methodology for infusion-related reactions with monoclonal antibodies. Clin Transl Immunology. 2015;4(7):e39.
   PubMedGoogle Scholar
• Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13(6):725–732.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis. Arthritis Res Ther. 2003;5(Suppl 4):S12–16.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Simeon V, Laurenti L, et al. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. Leuk Lymphoma. 2017;58(11):2633–2641.
   PubMed Web of Science ®Google Scholar
• Brown BA, Torabi M. Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre. Drug Saf. 2011;34(2):117–123.
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Stepanski EJ, Fortner BV, et al. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer. 2008;16(4):393–398.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–688.
   PubMed Web of Science ®Google Scholar
• Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12(5):601–609.
   PubMed Web of Science ®Google Scholar
• Conti F, Ceccarelli F. Perricone C, et al. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis. Rheumatology (Oxford). 2011;50(6):1148–1152.
   PubMed Web of Science ®Google Scholar
• Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoImmunity and Rituximab registry. Arthritis Rheum. 2010;62(8):2458–2466.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825–2833.
   PubMed Web of Science ®Google Scholar
• Montoya JE, Luna HG, Vergara NG, et al. Incidence of infusion-related reaction to monoclonal antibody rituximab: a national kidney and transplant institute experience. Ann Acad Med Singapore. 2012;41(3):125–126.
   PubMed Web of Science ®Google Scholar
• Jung JW, Kang HR, Lee SH, et al. The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital. Oncology. 2014;86(3):127–134.
   PubMed Web of Science ®Google Scholar
• Pritchard CH, Greenwald MW, Kremer JM, et al. Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study. BMC Musculoskelet Disord. 2014;15:177.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Fleischmann RM, Furst DE, et al. Longterm safety of Rituximab: final report of the Rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol. 2015;42(10):1761–1766.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222–233.
   PubMed Web of Science ®Google Scholar
• Tony HP, Burmester G. Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther. 2011;13(3):R75.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079–4088.
   PubMed Web of Science ®Google Scholar
• Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 2002;100(9):3115–3120.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–1174.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Burris HA 3rd, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 2000;95(10):3052–3056.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17(1):268–276.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92(6):1927–1932.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242.
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002;61(10):883–888.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Matucci A, Nencini F, et al. Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab. Int Arch Allergy Immunol. 2012;159(3):321–326.
   PubMed Web of Science ®Google Scholar
• Ma B, Ujjani C. The clinical development of obinutuzumab for the treatment of follicular lymphoma. Cancer Manag Res. 2017;9:103–113.
   PubMed Web of Science ®Google Scholar
• van der Kolk LE, Grillo-Lopez AJ, Baars JW, et al. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol. 2001;115(4):807–811.
   PubMed Web of Science ®Google Scholar
• Gutierrez A, Rodriguez J, Martinez J, et al. Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma. Leuk Lymphoma. 2006;47(1):111–115.
   PubMed Web of Science ®Google Scholar
• Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94(7):2217–2224.
   PubMed Web of Science ®Google Scholar
• Wing M. Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction. J Immunotoxicol. 2008;5(1):11–15.
   PubMed Web of Science ®Google Scholar
• Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331–1344.
   PubMed Web of Science ®Google Scholar
• Golay J, Da Roit F, Bologna L et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013;122(20):3482–3491.
   PubMed Web of Science ®Google Scholar
• Jones JD, Hamilton BJ, Skopelja S, et al. Induction of interleukin-6 production by rituximab in human B cells. Arthritis Rheumatol. 2014;66(11):2938–2946.
   PubMed Web of Science ®Google Scholar
• Moghimi SM. Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions. Drug Discov Today. 2018;23(5):1034–1042.
   PubMed Web of Science ®Google Scholar
• Bugelski PJ, Achuthanandam R, Capocasale RJ, et al. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol. 2009;5(5):499–521.
   PubMed Web of Science ®Google Scholar
• Norin S, Bjorkstrand B, Rommel F, et al. Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: results from a Swedish national observational study. Leuk Res. 2015;39(1):33–37.
   PubMed Web of Science ®Google Scholar
• Hayama T, Miura K, Uchiike A, et al. A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas. Int J Clin Pharm. 2017;39(2):380–385.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19(8):2153–2164.
   PubMed Web of Science ®Google Scholar
• Freeman CL, Dixon M. Houghton R, et al. Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab. Leukemia. 2016;30(8):1763–1766.
   PubMed Web of Science ®Google Scholar
• Vo KH, Waddell JA, Suda KJ. Rapid development of infusion-related severe hypotension during rituximab therapy. Ann Pharmacother. 2011;45(5):e29.
   PubMedGoogle Scholar
• Keating GM. Spotlight on rituximab in chronic lymphocytic leukemia, low-grade or follicular lymphoma, and diffuse large B-cell lymphoma. BioDrugs. 2011;25(1):55–61.
   PubMed Web of Science ®Google Scholar
• Arredondo-Garza T, Majluf-Cruz A, Vela-Ojeda J, et al. Peri-infusional adverse reactions to rituximab in patients with non-Hodgkin’s lymphoma. Arch Med Res. 2013;44(7):549–554.
   PubMed Web of Science ®Google Scholar
• Cho KM, Keam B, Ha H, et al. Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP. Korean J Intern Med. 2017.
   Web of Science ®Google Scholar
• Dakhil S, Hermann R, Schreeder MT, et al. Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma. Leuk Lymphoma. 2014;55(10):2335–2340.
   PubMed Web of Science ®Google Scholar
• Wong JT, Long A. Rituximab hypersensitivity: evaluation, desensitization, and potential mechanisms. J Allergy Clin Immunol Pract. 2017;5(6):1564–1571.
   PubMed Web of Science ®Google Scholar
• Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.
   PubMed Web of Science ®Google Scholar